Grants and Contributions:
Title:
Atopic Dermatitis Study in Dogs
Agreement Number:
914972
Agreement Value:
$34,263.60
Agreement Date:
Oct 17, 2018 - Nov 30, 2019
Description:
SMN-023 is new a topical therapy for canine atopic dermatitis. This study is designed to show proof of concept that SMN-023 can be the first pharmaceutical approved as a maintenance therapy to delay the onset of atopic dermatitis flares in dogs.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Whitby, Ontario, CA L1R 1V8
Reference Number:
172-2018-2019-Q3-914972
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
719672123
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is -48,301.4 dollars.
Amendment Date
Sep 3, 2019
Recipient's Legal Name:
Simini Technologies Inc.
Federal Riding Name:
Whitby
Federal Riding Number:
35114
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: